Latest News by Industry
Modular Medical, Inc. (OTCQB: MODD), a development-stage insulin pump company focused on providing insulin delivery without complexity to increase pump adoption and reduce the burden of diabetes care for clinicians and individuals living withdiabetes, today announced the expansion of its Board of Directors with the appointment of two independent directors, StevenG. Felsher and Philip B. Sheibley.
The Company’s Chief Executive Officer, Lynn O’Connor Vos, stated, “We are honored to have two executives with such depth and breadth of experience join the Board. The Company is committed to making insulin pump technology a cornerstone of better control for all people living with diabetes, with a particular focus on historically underserved communities. Our new Board members will provide invaluable expertise to help us bring our product to market.”
Steve Felsherhas over 30 years’ experience in finance, administration, governance, capital allocation and other aspects of public andprivate company management. Much of his career was spent at Grey Global Group Inc., a global marketing services company, where he served as Vice Chairman and Chief Financial Officer with responsibility for all non-client/non-media facing elements of the business, including financial management, human resources, capital formation, corporate development, investor relations and acquisitions. He also served almost a decade as active senior advisor at Quadrangle Group LLC where he oversaw fund investments in telecom, telecom services and media.
Philip B. Sheibleyis an experienced executive and venture capitalist. He spent 30 years as a management and technology consultant with Accenture, where he focused on the Life Sciences area, holding a variety of leadership positions, including North American Industry Director for Life Sciences and Global Lead for Management Consulting. Mr. Sheibley’s consulting work focused on defining and executing strategies to create leading-edge business capabilities, working with U.S. and internationally headquartered pharmaceutical companies, biotech, and medical product producers, as well as contract research organizations. He also played a leadership role in a number of joint-venture and new venture start-up engagements where company operating model and capability strategies needed to be defined for successful launch.